BioArctic AB (publ) (BRCTF PINK) stock market data APIs
$20.3934
0(0%)
as of May 2, 2025
BioArctic AB (publ) Financial Data Overview
BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company research and development of innovative biological drugs, such as antibodies, that address high unmet medical needs. Its therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, the company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, it develops lecanemab phase 3 clinical trial, Lecanemab back-up phase 3 clinical trial, BAN1503 is in discovery stage, and Exidavnemab is in phase 2 clinical trial, Lecanemab is in preclinical; and BAN2803, BAN2802 preclinical trial; PD-BT2238, ND-BT3814, and GD-BT6822 in discovery stage. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Prev. Close
20.3934
Open
20.3934
High
20.3934
Low
20.3934
52 wk Range
12.9435-24.8
Market Cap
1 780 M
Shares Outstanding
74 128 K
Revenue
257 M
EPS
-0.033
Beta
-0.671
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get BioArctic AB (publ) data using free add-ons & libraries
Get BioArctic AB (publ) Fundamental Data
BioArctic AB (publ) Fundamental data includes:
- Net Revenue: 257 M
- EBITDA: -211 190 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-13
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BioArctic AB (publ) News
New
European Growth Companies Insiders Are Eager To Own
In recent weeks, European markets have shown resilience, with the pan-European STOXX Europe 600 Index rising 3.93% as investor sentiment was buoyed by the European Central Bank's rate cuts and a delay...
High Growth Tech Stocks To Watch In Europe April 2025
As European markets grapple with the fallout from higher-than-expected U.S. trade tariffs, which have led to significant declines in major indices like the STOXX Europe 600 and Germany's DAX, investor...
The European Commission refers lecanemab decision to Appeal Committee
STOCKHOLM, April 1, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission (EC) has decided to refer the marketing authorisati...
3 European Growth Stocks With Insider Ownership Seeing Up To 52% Earnings Growth
As European markets experience a mix of modest gains and losses, with the pan-European STOXX Europe 600 Index rising slightly amid hopes for increased government spending, investors are navigating a l...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
